Story perspectives

Breakthrough Gene Therapy Revives Alzheimer’s Hope in Mice

6/9/2025

47 11

Summary

Story summary

Researchers at UC San Diego have made a groundbreaking leap in Alzheimer’s treatment with a gene therapy called AAV9-Synapsin-promoted Cav-1 (SynCav1). In mice, this innovative therapy not only preserved cognitive function but also transformed the behavior of diseased cells. While the results are encouraging, more research is essential before moving to human trials. Eikonoklastes Therapeutics has licensed this promising technology and previously secured FDA Orphan Drug Designation for ALS in 2022.

1 of 1

Story summary

Researchers at UC San Diego have made a groundbreaking leap in Alzheimer’s treatment with a gene therapy called AAV9-Synapsin-promoted Cav-1 (SynCav1). In mice, this innovative therapy not only preserved cognitive function but also transformed the behavior of diseased cells. While the results are encouraging, more research is essential before moving to human trials. Eikonoklastes Therapeutics has licensed this promising technology and previously secured FDA Orphan Drug Designation for ALS in 2022.